Biotech Values

[DewDiligence]

Scher’s best argument (IMO) is that the panel vote was contrary to what ODAC has done and potentially sets up a bifurcated approval threshold.

One of Scher’s weaker arguments is that approving Provenge could cause other trials in HRPC to use Provenge in the control arm. This is a weak argument because, if it turns out that Provenge is no better than a placebo, the trials in question will effectively be placebo-controlled.